Tia here with news that a trial of the pill form of the GLP-1 drug semaglutide has failed to delay Alzheimer's progression in ...

A pill version of A/S’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of long-shot studies that ...

Trials of semaglutide, the active ingredient in Ozempic and Wegovy, improve Alzheimer’s biomarkers but do not slow disease ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

Now, Clearside has filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for ...

The airline's aircraft was struck by bullets from rival gang fighting as it was trying to make a landing at the Caribbean ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Novo Nordisk shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial.

Novo Nordisk’s stock is experiencing a steep drop following major clinical setbacks and intensifying competitive pressure in ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

Eli Lilly and Novo Nordisk are collaborating with Waltz Health to launch direct-to-employer access for obesity management medications. Waltz Health gave no information on the prices of GLP-1 drugs ...